Wilmington, North Carolina, United States The main office of represented VC is situated in the Wilmington. The fund was located in North America if to be more exact in United States.
Among the most popular portfolio startups of the fund, we may highlight Dignify Therapeutics, Sapience Therapeutics, Sapience Therapeutics. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 3 or 4 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Developer Platform, Biotechnology.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Eshelman Ventures, startups are often financed by Mountain Group Capital, MedImmune Ventures, Hatteras Venture Partners. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, TaiAn Technologies, Mountain Group Capital. In the next rounds fund is usually obtained by Tavistock Life Sciences, TaiAn Technologies, Small Business Innovation Research.
This organization was formed by Fred Eshelman.
Considering the real fund results, this VC is 51 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Eshelman Ventures performs on 15 percentage points less the average number of lead investments. The higher amount of exits for fund were in 2017. When the investment is from Eshelman Ventures the average startup value is 10-50 millions dollars. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year.
Related Funds
| Fund Name | Location |
| Batlivala & Karani Securities | India, Maharashtra, Mumbai |
| Challenjers Capital | Beijing, Beijing, China |
| Coutts | England, London, United Kingdom |
| DHL | Bonn, Germany, Nordrhein-Westfalen |
| Goldmann International GmbH. | China, Gansu, Sichuan |
| Hub One | Champagne-Ardenne, France, Tremblay |
| Hutchison Kinrot | HaMerkaz, Israel, Netanya |
| Indo-US Venture Partners | California, Santa Clara, United States |
| Interactive Technology Holdings | China, Hong Kong, Hong Kong Island |
| Liby Group | China, Guangdong, Guangzhou |
| M10 GmbH | Berlin, Berlin, Germany |
| OSJL LLC | - |
| Reliance Life Insurance | India, Maharashtra, Mumbai |
| SDG Invest | - |
| Shenyang Xunan Technology | China, Liaoning, Shenyang |
| Springboard Ventures | Delaware, United States, Wilmington |
| Taihuoniao | Beijing, Beijing, China |
| The Social Internet Fund | New York, New York, United States |
| Wolsey Ventures | Genoa, Italy, Liguria |
| Yabao Investment | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Sapience Therapeutics | $41M | 31 May 2022 | New York, United States | ||
ARC Therapeutics | $30M | 31 Mar 2022 | Durham, North Carolina, United States | ||
Kinnate Biopharma | $74M | 19 Dec 2019 | San Diego, California, United States | ||
Kinnate Biopharma | $22M | 01 Apr 2018 | San Diego, California, United States | ||
Sapience Therapeutics | $22M | 12 Jul 2016 | New York, United States | ||
G1 Therapeutics | $47M | 11 May 2016 | Durham, North Carolina, United States | ||
Cellective BioTherapy | $2M | 12 Jun 2015 | Raleigh, North Carolina, United States | ||
G1 Therapeutics | $33M | 05 Feb 2015 | Durham, North Carolina, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Sapience Therapeutics | $41M | 31 May 2022 | New York, United States | ||
ARC Therapeutics | $30M | 31 Mar 2022 | Durham, North Carolina, United States | ||
Kinnate Biopharma | $74M | 19 Dec 2019 | San Diego, California, United States | ||
Kinnate Biopharma | $22M | 01 Apr 2018 | San Diego, California, United States | ||
Sapience Therapeutics | $22M | 12 Jul 2016 | New York, United States | ||
G1 Therapeutics | $47M | 11 May 2016 | Durham, North Carolina, United States | ||
Cellective BioTherapy | $2M | 12 Jun 2015 | Raleigh, North Carolina, United States | ||
G1 Therapeutics | $33M | 05 Feb 2015 | Durham, North Carolina, United States |
